Inhibition of human 2OG oxygenases by N-hydroxythiazole analogues bearing carbocyclic linkers.
| Entry | Cmpda |
|
IC50 [μM]b | ||||
|---|---|---|---|---|---|---|---|
| R | FIHc | AspHd | PHD2e | KDM4Af | JMJD5g | ||
| i | 20 |
|
1.0 ± 0.0 | 23.3 ± 10.1 | 6.5 ± 1.8 | >100 | 13.4 ± 6.5 |
| ii | 24 |
|
0.45 ± 0.17 | 60.9 ± 24.1 | 5.2 ± 0.7 | >100 | 29.1 ± 4.4 |
| iii | 25 |
|
1.2 ± 0.2 | >100 | 33.5 ± 1.0 | >100 | 32.6 ± 6.7 |
| iv | 26 |
|
0.50 ± 0.02 | 37.8 ± 11.3 | 12.4 ± 0.8 | >100 | 12.5 ± 1.0 |
| v | 27 |
|
0.87 ± 0.04 | 49.1 ± 1.7 | 11.0 ± 1.6 | >100 | 13.4 ± 1.0 |
| vi | 28 |
|
2.1 ± 1.5 | 24.9 ± 12.0 | 12.7 ± 1.8 | >100 | 2.6 ± 0.2 |
| vii | 29 |
|
>100 | >100 | >100 | >100 | >100 |
| viii | 30 |
|
1.7 ± 0.4 | >100 | 71.7 ± 26.6 | >100 | 25.6 ± 0.6 |
All chiral N-hydroxythiazole derivatives were prepared as racemic mixtures.
Mean average ± SD of two independent experiments (each composed of technical duplicates).
Using 0.15 μM FIH, 10.0 μM 2OG and 5.0 μM HIF-1α C-TAD788–822.61
Using 0.05 μM His6-AspH315–758, 3.0 μM 2OG and 1.0 μM hFX-CP101–119.58
Using 0.15 μM PHD2181–426, 10.0 μM 2OG and 5.0 μM HIF-1α CODD556–574.61
Using 0.15 μM KDM4A, 10.0 μM 2OG and 10.0 μM H31–15K9me31–15.69
Using 0.15 μM JMJD5, 2.0 μM 2OG and 2.0 μM RSP6128–148.70 Inhibition assays were performed using SPE-MS as described in the ESI.